Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
The Cleveland Clinic Novartis |
---|---|
Information provided by: | The Cleveland Clinic |
ClinicalTrials.gov Identifier: | NCT00264420 |
Zoledronic acid (Zometa) belongs to a class of drugs called bisphosphonates. Bisphosphonates are used in bone metastases to keep the cancerous lesion under control in the bone and to help prevent calcium level elevations in the blood. Cancer cell-culture studies at the Cleveland Clinic showed that zoledronic acid and radiation together have more cell killing effect than either one used alone. The purpose of this study is to monitor the healing of bone lesions when using zoledronic acid together with radiation treatment.
Condition | Intervention | Phase |
---|---|---|
Bone Metastases Breast Cancer Lung Cancer Prostate Cancer |
Drug: zoledronic acid |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer |
Estimated Enrollment: | 30 |
Study Start Date: | December 2005 |
Bone metastases are frequently one of the first signs of disseminated disease in cancer patients. Skeletal complications due to metastatic disease include (severe) bone pain, impaired mobility, spinal cord compression, pathological fractures, and hypercalcemia. Radiotherapy and surgery are the options for the specific local treatment of bone metastases. Chemotherapy, hormonotherapy and bisphosphonates are systemic weapons used in the treatment of bone metastases with or without hypercalcemia. Cancers with propensity to metastasize to bones such as breast, prostate, lung and myeloma may possess the capacity to interact with osteoclasts. Osteoclasts are specialized bone cells, which erode mineralized bone by secreting acids and lysosomal enzymes. In normal bone remodeling, osteoclastic bone resorption is coupled to and is in equilibrium with osteoblastic bone formation. The lytic bone destruction associated with malignant bone metastases develops because tumor cells synthesize and release soluble factors that stimulate osteoclasts to resorb bone. The malignant activation of osteoclasts results in a disruption of normal bone remodeling wherein the equilibrium between bone resorption and bone formation is shifted toward increased bone resorption. This relative increase in osteoclastic bone resorption results in a net loss of bone.
Zoledronic acid (Zometa®, CGP42446) is a member of a class of compounds known as bisphosphonates. Bisphosphonates are effective inhibitors of osteoclastic bone resorption. They have therapeutic efficacy in the treatments of hypercalcemia of malignancy, lytic bone disease associated with multiple myeloma, and mixed lytic and blastic bone metastases associated with breast cancer, prostate cancer and lung cancer. In the clinical setting, zoledronic acid is the most potent bisphosphonate.
Conventionally, external beam radiotherapy (RT) is a primary treatment method for the palliation of bone metastases. The aim of RT in bone metastases treatment is to eradicate malignant cells without damaging surrounding normal cells. RT is typically given to the lesion area, in order to spare as much bone marrow as possible. RT is indicated in solitary, lytic and painful bone lesions of multiple myeloma as well as bone metastases from solid tumors such as breast, prostate and lung cancer to prevent the fracture risk or to relieve the pain.
The goal of this study will be to evaluate the safety and efficacy of concomitant standard RT and standard zoledronic acid on the bone metastases of breast, prostate or lung cancer patients. We chose zoledronic acid to use in this study, as it is the most effective FDA approved aminobisphosphonate.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Roger Macklis, MD | 216-444-5576 | macklir@ccf.org |
Contact: Ruth Cocirteu, RN | 216-445-5053 | cocirtr@ccf.org |
United States, Ohio | |
Cleveland Clinic Foundation | Recruiting |
Cleveland, Ohio, United States, 44195 | |
Contact: Roger Macklis, MD 216-444-5576 macklir@ccf.org | |
Contact: Ruth Cocirteu, RN 216-445-5053 cocirtr@ccf.org |
Principal Investigator: | Roger Macklis, MD | The Cleveland Clinic |
Study ID Numbers: | IRB7743, Case 8Y04 |
Study First Received: | December 6, 2005 |
Last Updated: | January 17, 2006 |
ClinicalTrials.gov Identifier: | NCT00264420 |
Health Authority: | United States: Institutional Review Board |
bone metastases breast cancer lung cancer |
prostate cancer zoledronic acid radiation therapy |
Thoracic Neoplasms Zoledronic acid Prostatic Diseases Bone Neoplasms Skin Diseases Genital Neoplasms, Male Hematologic Diseases Bone neoplasms Breast Neoplasms Urogenital Neoplasms Genital Diseases, Male |
Bone Diseases Diphosphonates Musculoskeletal Diseases Respiratory Tract Diseases Lung Neoplasms Lung Diseases Neoplasm Metastasis Bone Marrow Diseases Prostatic Neoplasms Breast Diseases |
Respiratory Tract Neoplasms Neoplastic Processes Neoplasms Pathologic Processes |
Neoplasms by Site Physiological Effects of Drugs Bone Density Conservation Agents Pharmacologic Actions |